Investor Relations (IR) Questions: InSite Vision INSV
Click here to return to the biotech IRQ Index
Answers received: August 2013
1) When is the last time INSV raised cash through an offering (diluted)? We did a PIPE in July 2011.
2) How much cash (not cash equivalents) does INSV have? $14.6 million at June 30, 2013. I don’t know why you’d differentiate between cash and cash equivalents. Our cash equivalents are all highly liquid and earn interest; cash does not.
3) What and approximately when is the next known catalyst? FDA meeting on DOUBle Phase 3 Study, August 19, 2013
4) What is INSV's quarterly cash burn? Q2 $4.4 million which included a $2.7 million principal payment on our NON-RECOURSE notes. Our cash usage from operations in Q2 was $1.7 million.
5) Does INSV have an existing line of credit and if so how much can they draw against it? No.
1) When is the last time INSV raised cash through an offering (diluted)? We did a PIPE in July 2011.
2) How much cash (not cash equivalents) does INSV have? $14.6 million at June 30, 2013. I don’t know why you’d differentiate between cash and cash equivalents. Our cash equivalents are all highly liquid and earn interest; cash does not.
3) What and approximately when is the next known catalyst? FDA meeting on DOUBle Phase 3 Study, August 19, 2013
4) What is INSV's quarterly cash burn? Q2 $4.4 million which included a $2.7 million principal payment on our NON-RECOURSE notes. Our cash usage from operations in Q2 was $1.7 million.
5) Does INSV have an existing line of credit and if so how much can they draw against it? No.
Answers received: January 2013
1) When is the last time INSV raised cash through an offering (diluted)? July 2011
2) How much cash (not cash equivalents) does INSV have? Very little, maybe $100,000 in our checking account. We have cash equivalents, all short-term, easily sold US treasury securities, that are equal to 100X our checking account balance.
3) What and approximately when is the next known catalyst? The top line results from the Phase 3 clinical trial for BromSite which is expected this quarter. In early January, we announced that the last patent in this trial had exited the study. We expect to see the Phase 3 Double study results in the second quarter 2013.
4) What is INSV's quarterly cash burn? About $2 million a quarter when we are not doing clinical trials.
5) Does INSV have an existing line of credit and if so how much can they draw against it? No.
1) When is the last time INSV raised cash through an offering (diluted)? July 2011
2) How much cash (not cash equivalents) does INSV have? Very little, maybe $100,000 in our checking account. We have cash equivalents, all short-term, easily sold US treasury securities, that are equal to 100X our checking account balance.
3) What and approximately when is the next known catalyst? The top line results from the Phase 3 clinical trial for BromSite which is expected this quarter. In early January, we announced that the last patent in this trial had exited the study. We expect to see the Phase 3 Double study results in the second quarter 2013.
4) What is INSV's quarterly cash burn? About $2 million a quarter when we are not doing clinical trials.
5) Does INSV have an existing line of credit and if so how much can they draw against it? No.